Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 1/20 | 0.43 |
| ▸ | NOD1 | Q9Y239 | 9/20 | 0.41 |
| ▸ | FNTA | P49354 | 1/20 | 0.38 |
| ▸ | FNTB | P49356 | 1/20 | 0.38 |
| ▸ | DPP4 | P27487 | 1/20 | 0.38 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.38 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | BLM | P54132 | 1/20 | 0.38 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22069889 | 0.89 | LTA4H (0.46) | LTA4HNOD1DPP4DPP8DPP9 | |
| SCHEMBL9689060 | 0.89 | KMT2A (0.43) | LTA4HNOD1KMT2APOLBL3MBTL1 | |
| SCHEMBL10421150 | 0.89 | KMT2A (0.43) | LTA4HNOD1KMT2APOLBL3MBTL1 | |
| SCHEMBL10421162 | 0.89 | KMT2A (0.43) | LTA4HNOD1KMT2APOLBL3MBTL1 | |
| SCHEMBL9688654 | 0.89 | KMT2A (0.43) | LTA4HNOD1KMT2APOLBL3MBTL1 | |
| SCHEMBL7496434 | 0.89 | KMT2A (0.43) | LTA4HNOD1KMT2APOLBL3MBTL1 | |
| SCHEMBL9689026 | 0.89 | KMT2A (0.43) | LTA4HNOD1KMT2APOLBL3MBTL1 | |
| SCHEMBL20732328 | 0.89 | LTA4H (0.46) | LTA4HNOD1DPP4DPP8DPP9 | |
| SCHEMBL1261014 | 0.85 | KMT2A (0.50) | LTA4HFNTAFNTBDPP4DPP8 | |
| SCHEMBL594919 | 0.85 | KMT2A (0.50) | LTA4HFNTAFNTBDPP4DPP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230165932-A1 | PCSK9 ANTAGONIST COMPOUNDS | MERCK SHARP & DOHME LLC | 2023-06-01 | — | — | US | disclosed |
| US-20210069288-A1 | PCSK9 ANTAGONIST COMPOUNDS | MERCK SHARP & DOHME LLC | 2021-03-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210069288-A1 | PCSK9 ANTAGONIST COMPOUNDS | PCSK9, PCSK7, PCSK6 | LTA4H 1663/4885NOD1 1215/4885FNTA 1376/4885 |
| US-20230165932-A1 | PCSK9 ANTAGONIST COMPOUNDS | PCSK9, PCSK7, PCSK6 | LTA4H 1663/4885NOD1 1215/4885FNTA 1376/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.